Sunday 11 October 2026 Export all MRK data to Excel Powerpack

Merck & Co., Inc.

MRK Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.

145.60 3.22 +2.26%
Market cap
$351.3B
P/E
116×
Fwd P/E
53.9×
Dividend yield
2.34%
F-score
4/9
Altman Z
3.77
Beneish M
−2.27
Dividend safety
74/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

39.46% 36.86% 18.94% 6.97%
Piotroski F-Score
6 4 4 4
ROA
15.41% 14.37% 7.33% 2.57%
ROIC
19.00% 16.28% 9.33% 5.08%
Return on Tangible Assets
42.71% 45.07% 26.67% 9.15%
Average Days of Receivables
68.87 66.11 67.76 68.89
Free Cash Flow per Share
5.23 4.94 5.71 6.50
Free Cash Flow
13,049.00 12,360.00 14,115.00 16,063.00
Capital Expenditures
(4,016.00) (4,112.00) (3,775.00) (3,904.00)
Other line items
Cash ROIC
11.85% 10.84% 14.36% 16.03%
Accounts Receivable Turnover
5.47 5.90 5.72 5.45
Accounts Payable Turnover
3.79 3.86 4.49 4.66
Inventory Turnover
2.31 2.57 2.71 2.81
Average Days of Payables
103.26 98.12 82.18 77.62
Days of Inventory on Hand
160.45 148.34 137.83 125.89
Tax Rate
(0.13) (0.13) (0.23) (0.47)
Research and Development Expense of Revenue
25.67% 24.29% 37.65% 45.75%
Selling, General and Administrative Expense of Revenue
16.65% 16.51% 16.54% 16.73%
Share Based Compensation of Revenue
1.25% 1.26% 1.23% 1.34%
Operating CF/Net income
0.90 0.90 2.00 6.29
Depreciation/Fixed assets
0.18 0.23 0.25 0.26
Capex/Depreciation
(0.88) (0.70) (0.60) (0.58)
Revenue per Share
25.75 25.98 26.61 26.95
Operating CF per Share
6.84 6.58 7.24 8.08
Capex per Share
(1.61) (1.64) (1.53) (1.58)
Capex to Sales
0.06 0.06 0.06 0.06

Fold the line items

Columns are period end dates